Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
diagnosis
|
| gptkbp:advantage |
easy to use
rapid results no need for laboratory equipment |
| gptkbp:alsoKnownAs |
gptkb:LFA
lateral flow immunoassay |
| gptkbp:application |
COVID-19 testing
drug testing infectious disease detection pregnancy test |
| gptkbp:component |
absorbent pad
conjugate pad control line nitrocellulose membrane sample pad test line |
| gptkbp:detects |
nucleic acids
antibodies antigens colorimetric detection fluorescence detection haptens visual readout |
| https://www.w3.org/2000/01/rdf-schema#label |
lateral flow assay
|
| gptkbp:inventedBy |
gptkb:Unipath
1980s |
| gptkbp:limitation |
lower sensitivity than laboratory tests
potential for false negatives potential for false positives qualitative or semi-quantitative results |
| gptkbp:manufacturer |
gptkb:Siemens_Healthineers
gptkb:BD gptkb:Roche gptkb:Abbott gptkb:Quidel |
| gptkbp:regulates |
CE marking (for EU market)
FDA (for US market) |
| gptkbp:relatedTo |
gptkb:ELISA
point-of-care testing immunochromatography rapid antigen test |
| gptkbp:type |
blood
urine saliva nasal swab throat swab |
| gptkbp:usedFor |
point-of-care testing
rapid diagnostic testing |
| gptkbp:usedIn |
environmental testing
food safety testing veterinary diagnostics human diagnostics |
| gptkbp:市值 |
multi-billion dollar industry
|
| gptkbp:bfsParent |
gptkb:ELISA
gptkb:immunoassay |
| gptkbp:bfsLayer |
5
|